Adrecizumab

Sepsis-Therapie

Adrecizumab ist ein humanisierter Antikörper, der spezifisch das körpereigene Peptidhormon Adrenomedullin (ADM) bindet. Dabei wird dessen Bioaktivität nicht völlig blockiert, sondern lediglich auf ein gesundheitsförderliches Maß gehemmt. Damit ist Adrecizumab der erste Wirkstoff, der bei einer schweren Sepsis den gesamten Kreislauf stabilisiert. Der Überschuss an ADM bei einer Sepsis führt zu einer überschießenden Gefäßerweiterung, die wiederum eine verminderte Durchblutung und damit einen gefährlichen Blutdruckabfall zur Folge hat. Werden die Organe nicht ausreichend durchblutet, kommt es schließlich zum multiplen Organversagen oder septischen Schock, der allein in Deutschland in über 60.000 Fällen pro Jahr tödlich verläuft.

Die präklinischen Ergebnisse mit Adrecizumab sind vielversprechend. So verbesserte sich unter Adrecizumab die Nierenfunktion und damit der Flüssigkeitshaushalt des Körpers, der Blutdruck wurde stabilisiert, die gefährlichen Entzündungsreaktionen verringerten sich und es kam zu weniger Gefäßschädigungen. Insgesamt konnte in den Tierversuchen die Sterblichkeit um 50 Prozent reduziert werden.

Adrecizumab soll zur ursächlichen und sicheren Behandlung von Sepsis-Patienten eingesetzt werden. Nach dem sehr erfolgreichen Verlauf und den vielversprechenden Ergebnissen der präklinischen Studien, bereitet die DBI derzeit die klinische Phase-I-Studie vor, die voraussichtlich Ende 2015 starten wird.

Präklinische Ergebnisse

Blutdruck von gesunden Mäusen in mmHg (Gesunde Kontrolle) und von Mäusen nach Sepsis-Induktion (CLP-Modell), jeweils nach Placebo- und Adrecizumab-Gabe.
Blutdruck von gesunden Mäusen in mmHg (Gesunde Kontrolle) und von Mäusen nach Sepsis-Induktion (CLP-Modell), jeweils nach Placebo- und Adrecizumab-Gabe.
Überlebensrate von Mäusen nach Sepsis-Induktion (CLP-Modell) mit und ohne Adrecizumab-Gabe. Siehe Struck et al. Intensive Care Medicine Experimental 2013, 1:3.
Überlebensrate von Mäusen nach Sepsis-Induktion (CLP-Modell) mit und ohne Adrecizumab-Gabe. Siehe Struck et al. Intensive Care Medicine Experimental 2013, 1:3.
 
 

Literatur

Wagner et al. Intensive Care Medicine Experimental 2013, 1:2

Adrenomedullin binding improves catecholamine responsiveness and kidney function in resuscitated murine septic shock

Katja Wagner, Ulrich Wachter, Josef A Vogt, Angelika Scheuerle, Oscar McCook, Sandra Weber, Michael Gröger, Bettina Stahl, Michael Georgieff, Peter Möller, Andreas Bergmann, Frauke Hein, Enrico Calzia, Peter Radermacher, Florian Wagner

Intensive Care Med Exp. 2013, 1:2

Download PDF


ABSTRACT

PURPOSE: Adrenomedullin (ADM) has been referred to as a double-edged sword during septic shock: On one hand, ADM supplementation improved organ perfusion and function, attenuated systemic inflammation, and ultimately reduced tissue apoptosis and mortality. On the other hand, ADM overproduction can cause circulatory collapse and organ failure due to impaired vasoconstrictor response and reduced myocardial contractility. Since most of these data originate from un-resuscitated shock models, we tested the hypothesis whether the newly developed anti-ADM antibody HAM1101 may improve catecholamine responsiveness and thus attenuate organ dysfunction during resuscitated murine, cecal ligation and puncture (CLP)-induced septic shock.

METHODS: Immediately after CLP, mice randomly received vehicle (phosphate-buffered saline, n = 11) or HAM1101 (n = 9; 2 μg·g(-1)). Fifteen hours after CLP, animals were anesthetized, mechanically ventilated, instrumented, and resuscitated with hydroxyethylstarch and continuous i.v. norepinephrine to achieve normotensive hemodynamics (mean arterial pressure > 50 to 60 mmHg).

RESULTS: HAM1101 pretreatment reduced the norepinephrine infusion rates required to achieve hemodynamic targets, increased urine flow, improved creatinine clearance, and lowered neutrophil gelatinase-associated lipocalin blood levels, which coincided with reduced expression of the inducible nitric oxide synthase and formation of peroxynitrite (nitrotyrosine immunostaining) in the kidney and aorta, ultimately resulting in attenuated systemic inflammation and tissue apoptosis.

CONCLUSIONS: During resuscitated murine septic shock, early ADM binding with HAM1101 improved catecholamine responsiveness, blunted the shock-related impairment of energy metabolism, reduced nitrosative stress, and attenuated systemic inflammatory response, which was ultimately associated with reduced kidney dysfunction and organ injury.

Struck et al. Intensive Care Medicine Experimental 2013, 1:3

Epitope specificity of anti-Adrenomedullin antibodies determines efficacy of mortality reduction in a cecal ligation and puncture mouse model  

Joachim Struck, Frauke Hein, Siegmund Karasch, Andreas Bergmann 

Intensive Care Med Exp. 2013, 1:3 

Download PDF


ABSTRACT

INTRODUCTION: Adrenomedullin (ADM), a circulating vasodilatory peptide, plays an important role in the development of sepsis-associated hemodynamic and microcirculatory disorders. While administration of exogenous ADM had beneficial effects in several septic animal models, elevated ADM concentrations are associated with a bad outcome. This prompted us to test the effect of various anti-ADM antibodies in a cecal ligation and puncture (CLP) mouse model.

METHODS: To gain new potential compounds for the treatment or prevention of septic shock we followed an alternative strategy to influence the ADM system: High-affinity anti-ADM antibodies with different epitope specificities were developed and their antagonist activity in vitro and their ability to reduce mortality in a CLP mouse model were assessed.

RESULTS: An anti-ADM antibody directed against the N-terminus substantially increased the survival of mice in a CLP model (HR = 0.077 (CI = 0.0189 to 0.315), p = 0.0004), whereas other antibodies with similar affinities but different epitope specificities were much less potent. The efficacious antibody, in contrast to an anti-C-terminal antibody, only partially inhibited ADM agonist activity in vitro. Healthy mice were not negatively affected by the N-terminal antibody. CONCLUSIONS: An anti-N-terminal ADM antibody, as opposed to antibodies with other epitope specificities, strongly reduces mortality in CLP mice.

Marino et al. Critical Care 2014, 18(1):R34

Plasma adrenomedullin is associated with short-term mortality and vasopressor requirement in patients admitted with sepsis

Rossella Marino, Joachim Struck, Alan S Maisel, Laura Magrini, Andreas Bergmann and Salvatore Di Somma

Critical Care 2014, 18(1):R34

Download PDF


ABSTRACT

INTRODUCTION: The incidence of death among patients admitted for severe sepsis or septic shock is high. Adrenomedullin (ADM) plays a central role in initiating the hyperdynamic response during the early stages of sepsis. Pilot studies indicate an association of plasma ADM with the severity of the disease. In the present study we utilized a novel sandwich immunoassay of bioactive plasma ADM in patients hospitalized with sepsis in order to assess the clinical utility.

METHODS: We enrolled 101 consecutive patients admitted to the emergency department with suspected sepsis in this study. Sepsis was defined by fulfillment of at least two systemic inflammatory response syndrome (SIRS) criteria plus clinical suspicion of infection. Plasma samples for ADM measurement were obtained on admission and for the next four days. The 28-day mortality rate was recorded.

RESULTS: ADM at admission was associated with severity of disease (correlation with Acute Physiology and Chronic Health Evaluation II (APACHE II) score: r = 0.46; P <0.0001). ADM was also associated with 28-day mortality (ADM median (IQR): survivors: 50 (31 to 77) pg/mL; non-survivors: 84 (48 to 232) pg/mL; P <0.001) and was independent from and additive to APACHE II (P = 0.02). Cox regression analysis revealed an additive value of serial measurement of ADM over baseline assessment for prediction of 28-day mortality (P < 0.01). ADM was negatively correlated with mean arterial pressure (r = -0.39; P <0.0001), and it strongly discriminated those patients requiring vasopressor therapy from the others (ADM median (IQR): no vasopressors 48 (32 to 75) pg/mL; with vasopressors 129 (83 to 264) pg/mL, P <0.0001).

CONCLUSIONS: In patients admitted with sepsis, severe sepsis or septic shock plasma ADM is strongly associated with severity of disease, vasopressor requirement and 28-day mortality.

Produktpipeline

Mehr über den aktuellen Stand der gesamten DBI AG Produktpipeline.

DB1RA

Brustkrebsprävention

AB2302

Krebstherapie